Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT)

Anticancer Drug Des. 1999 Dec;14(6):517-38.

Abstract

Antibody- and gene-directed enzyme prodrug therapy are two-step targeting strategies designed to improve the selectivity of antitumour agents. The approaches are based on the activation of specially designed prodrugs by antibody-enzyme conjugates targeted to tumour-associated antigens (ADEPT) or by enzymes expressed by exogenous genes in tumour cells (GDEPT). Herein the design, synthesis, physico-chemical and biological properties, kinetics and clinical trials of the prodrugs and the enzymes carboxypeptidase G2 and nitroreductase are reviewed for ADEPT and GDEPT.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antibodies, Neoplasm / immunology
  • Drug Design
  • Genetic Therapy / methods*
  • Humans
  • Immunotherapy / methods*
  • Neoplasms / therapy*
  • Prodrugs*

Substances

  • Antibodies, Neoplasm
  • Prodrugs